Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N J Meropol

Showing results (11-20 of 69) with videos related to

Pageof 7
Sort By:
Cancer Immunology, Immunotherapy : CII|September 1, 1996
Diabetes mellitus induced by low-dose interleukin-2N Soni, N J Meropol, M Porter, et al.
Oncology (Williston Park, N.Y.)|February 12, 1998
Oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancerN J Meropol, D Noel, D S Sonnichsen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
A pilot study of early hospital discharge in adult patients with fever and neutropeniaN J Meropol, K R Fox, D J Vaughn, et al.
American Journal of Clinical Oncology|June 1, 1996
A pilot trial of 5-FU, leucovorin, and cisplatin with or without adriamycin in advanced cancerD J Vaughn, N J Meropol, B Armstead, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 1999
Paradoxical correlations of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 in metastatic colorectal carcinomaJ D Cheng, B A Werness, J S Babb, et al.
Current Treatment Options in Oncology|June 12, 2002
Pancreatic cancerS J Cohen, W H Pinover, J C Watson, et al.
Theoretical Medicine and Bioethics|November 19, 2003
Patient expectations of benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconceptionK P Weinfurt, D P Sulmasy, K A Schulman, et al.
Current Oncology (Toronto, Ont.)|January 4, 2020
Patient-physician discordance in goals of care for patients with advanced cancerS L Douglas, B J Daly, N J Meropol, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancerN J Meropol, D S Sonnichsen, M J Birkhofer, et al.
Cancer|April 3, 2001
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinomaN J Meropol, D Niedzwiecki, D Hollis, et al.
Pageof 7

Showing results (11-20 of 69) with videos related to

Sort By:
Pageof 7
Cancer Immunology, Immunotherapy : CII|September 1, 1996
Diabetes mellitus induced by low-dose interleukin-2N Soni, N J Meropol, M Porter, et al.
Oncology (Williston Park, N.Y.)|February 12, 1998
Oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancerN J Meropol, D Noel, D S Sonnichsen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
A pilot study of early hospital discharge in adult patients with fever and neutropeniaN J Meropol, K R Fox, D J Vaughn, et al.
American Journal of Clinical Oncology|June 1, 1996
A pilot trial of 5-FU, leucovorin, and cisplatin with or without adriamycin in advanced cancerD J Vaughn, N J Meropol, B Armstead, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 1999
Paradoxical correlations of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 in metastatic colorectal carcinomaJ D Cheng, B A Werness, J S Babb, et al.
Current Treatment Options in Oncology|June 12, 2002
Pancreatic cancerS J Cohen, W H Pinover, J C Watson, et al.
Theoretical Medicine and Bioethics|November 19, 2003
Patient expectations of benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconceptionK P Weinfurt, D P Sulmasy, K A Schulman, et al.
Current Oncology (Toronto, Ont.)|January 4, 2020
Patient-physician discordance in goals of care for patients with advanced cancerS L Douglas, B J Daly, N J Meropol, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancerN J Meropol, D S Sonnichsen, M J Birkhofer, et al.
Cancer|April 3, 2001
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinomaN J Meropol, D Niedzwiecki, D Hollis, et al.
Pageof 7